NCT06028087Recruiting
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Real-World Mapping Antithrombotic Regimens in Multiple Myeloma Patients on Treatment (The MAMMOTH Study of the GIMEMA Working Party on Hemostasis and Thrombosis)
Source: ClinicalTrials.gov · Last updated 14 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 736 (estimated)
- First submitted
- 31 Aug 2023
- Start date
- 10 Mar 2025
- Primary completion date
- 31 Mar 2030
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Diseases
- Multiple myeloma
- NCT number
- NCT06028087
What you commit to
- Study type: Observational
- Planned participants: 736
- From 10 Mar 2025 to the primary completion date, 31 Mar 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients having had thrombosis within 6 months before diagnosis of MM
- Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs)
Other
- Ongoing first active treatment for MM initiated before the starting of the study.
Who the study is looking for
- Age equal to or greater than 18 years of age.
- New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group
- First active treatment for MM started after recruitment in the study
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di Ematologia Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.